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Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system, traditionally considered to be an autoimmune, demyelinating disease. Based on this 
understanding, initial therapeutic strategies were directed at immune modulation and inflam-
mation control. At present, there are five licensed first-line disease-modifying drugs for MS 
in Europe, and two second-line treatments. Currently available MS therapies have shown 
significant efficacy throughout many trials, but they produce different side effects. Despite 
disease-modifying drugs being well known and safe, they require regular and frequent paren-
teral administration and are associated with limited long-term treatment adherence. Therefore, 
the development of new therapeutic strategies is warranted. Several oral compounds are in late 
stages of development for treating MS. Fingolimod is an oral sphingosine-1-phosphate receptor 
modulator that has demonstrated superior efficacy compared with placebo and interferon β-1a 
in phase III studies. It has already been approved in the treatment of MS. This review focuses 
on advances in current and novel oral treatment approaches in MS. We summarily review the 
oral compounds in this study, focusing on the recent development, approval, and the clinical 
experience with fingolimod.
Keywords: multiple sclerosis, oral compounds, fingolimod, sphingosine-1-phosphate, patient 
satisfaction, adherence
Introduction
Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease of the 
central nervous system (CNS). The worldwide incidence of MS is rising and is cur-
rently estimated to be about 3.6/100,000 person-years in women and 2.0/100,000 
 person-years in men. The female preponderance, common to many autoimmune 
diseases, is increasing, from an estimated 1.4 in 1955 to 2.3 in 2000.1
Although there is this wide incidence variability, MS is still the most common non-
traumatic cause of neurological disability and impairment in young patients in Western 
Europe and North America.2 Most patients (80%) present with a relapsing and remitting 
course (RRMS), which is characterized by recurring attacks of acute focal neurological 
deficits or exacerbations of existing deficits (relapses), followed gradually by partial 
or full recovery (remission).3 The multifocal nature of the disease manifests clinically 
as a range of sensorimotor, cerebellar, visual, sphincteric, brain stem, cognitive, and 
neuropsychiatric symptoms. After 10–20 years, approximately half of these patients 
convert to the secondary progressive (SPMS) phase of the  disease, in which there is 
acceleration of disability accumulating irreversible neurologic deficits in the absence of 
clinical relapses.4 The remaining 20% with progressive clinical deterioration from the 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
73
R E V I E w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/TCRM.S17426
 
Th
er
ap
eu
tic
s 
an
d 
Cl
in
ica
l R
isk
 M
an
ag
em
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
10
8.
70
.6
 o
n 
09
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Therapeutics and Clinical Risk Management 2013:9
onset of the disease have primary progressive MS (PPMS). 
Even though the immunopathogenesis of MS is complex and 
still unclear, it has been supposed that RRMS is character-
ized by strong inflammation activity, and PPMS and SPMS 
are thought to be dominated by axonal degeneration in the 
absence of overt inflammation, which is most likely a result 
of oxidative damage and/or increased susceptibility to injury 
caused by the process of loosening of the myelin sheath.5 
Many different immune cells are involved in the pathogen-
esis of MS, including T cells, B cells, and  macrophages.6 
Given the prominence of inflammatory changes in acute 
MS lesions, therapy for the disease has focused particularly, 
for the past three decades, on anti-inflammatory strategies. 
Thus, eight compounds have nowaday licenses for treating 
MS, and they especially target the inflammatory component 
of the disease. Treatment of RRMS typically consists of direct 
symptom management, brief corticosteroid administration for 
acute exacerbations, and the regular use of disease modifying 
drugs (DMDs). Currently approved immumomodulator treat-
ments for RRMS include glatiramer acetate (GA)  (Copaxone) 
and recombinant beta interferons (IFNβs) (IFNβ-1a, Avonex; 
IFNβ-1a, Rebif; IFNβ-1b, Betaseron, Extavia) that rep-
resent the gold standard in modifying the course of MS. 
Natalizumab (Tysabri), mitoxantrone  (Novantrone), and 
fingolimod (Gilenya) are also available for treatment of MS 
as second-line therapy in more severe disease. Since MS is a 
currently incurable, chronic disease, long-term DMD therapy 
is required, necessitating commitment from patients to con-
tinue their treatment indefinitely. At present, most approved 
MS treatments are injected (subcutaneously or intramus-
cularly) or are given by intravenous infusion, which can be 
associated with reduced convenience, compliance, and with 
injection- or infusion-related adverse reactions.7 Moreover, 
in clinical practice, DMDs or immunosuppressive treat-
ments are frequently associated with suboptimal response in 
terms of efficacy. The existing medications are only partially 
effective in halting MS relapses and in particular disability 
progression. Given the limitations of current interventions, 
management of MS could be significantly improved by new 
treatments that influence not only the immune system but also 
the pathologic changes in the CNS while also being amenable 
to oral administration, possibly avoiding the drawbacks of 
parenteral administration. Thus, there is an important need 
for new therapeutic strategies, not only those that may offer 
greater patient satisfaction, such as oral medications and 
monoclonal antibodies, but also agents intended to promote 
neuroprotection and neurorepair. Fingolimod (FTY720), the 
first oral drug approved, could combine both these aspects. 
Here, we briefly review compounds that have successfully 
completed first phase III clinical trials and then focus on 
FTY720 and how its recent approval will change the treat-
ment paradigm.
Oral MS therapies in development
A number of potential therapies for MS are now in late-stage 
development. New and novel therapeutic agents are being 
trialed in MS centers worldwide. These include not only oral 
agents for relapsing and progressive forms of the disease but 
also monoclonal antibodies. To improve patient adherence to 
DMD and especially to make their therapeutic compliance 
and quality of life better, clearly oral agents – if at least as 
effective as or even more effective than the currently available 
injectable therapies – would be a welcome advance. Several 
oral therapies are under evaluation in clinical trials. Currently, 
the most promising agents are listed in Table 1. Among these 
compounds, two agents have already been considered by 
regulatory agencies (fingolimod, cladribine), with different 
outcomes. Regulatory applications for fingolimod were sub-
mitted in December 2009, and the drug received approval from 
the FDA on September 21, 2010.8 On January 20, 2011, the 
Committee for Medicinal  Products for Human Use (CHMP) 
adopted a positive opinion, recommending the granting of 
a marketing authorization for fingolimod, intended for the 
treatment of adult patients with RRMS with high disease 
activity. At present, fingolimod is available in Russia, the US, 
and Europe. Applications for cladribine as an oral therapy 
for MS were submitted to the European Medicines Agency 
(EMA) and the FDA in 2009. Although additional informa-
tion was given, cladribine received a negative European 
recommendation from the CHMP on September 23, 2010 
(http://www.merckserono.com/corp.merckserono_2011/en/
images/20100924_en_tcm1494_59896.pdf?Version=).9
Cladribine, a synthetic deoxyadenosine analogue, is 
an oral immunomodulatory agent that produces targeted, 
sustained reduction of T and B lymphocytes. Short-course 
therapy with cladribine tablets was investigated for RRMS 
in the phase III CLARITY (Cladribine Tablets Treating 
Multiple Sclerosis Orally) study. The cladribine tablets’ 
dosing regimen consisted of two or four short courses per year 
(cumulative doses of 3.5 and 5.35 mg/kg over the 96-week 
study, respectively). Treatment with 3.5 and 5.25 mg/kg 
cladribine tablets significantly reduced the annualized relapse 
rate (relative reduction 57.6% and 54.5% vs placebo, 
respectively, both P , 0.001) and resulted in significantly 
more relapse-free patients (79.7% and 78.9% vs 60.9%, 
respectively; odds ratios 2.53 and 2.43; both P , 0.001).10 
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Three measures were detected on magnetic resonance 
 imaging (MRI) activity: T
1
 gadolinium-enhancing (Gd+) 
lesions, active T
2
 lesions, and combined unique lesions 
(all P , 0.001 vs placebo). Lymphopenia occurred more 
frequently in patients treated with cladribine tablets at both 
dosages than with placebo.11
Fumaric acid is an unsaturated dicarboxylic acid, isomeric 
to maleic acid, which acts as an intermediate in the Krebs 
cycle. Its exact mechanism of action is still unclear, but it 
appears to induce depletion of peripheral blood leukocytes, 
owing mainly to a reduction in the number of T cells. In vitro 
studies indicate that fumaric acid esters induce a shift from 
T-helper (Th)1 to Th2 cytokines as part of their treatment 
effect. Current evidence suggests that BG-12 is a potent acti-
vator of Nrf2, a transcription factor of a major cytoprotective 
(neuroprotective) and anti-inflammatory pathway.12 In a phase 
IIb study, 257 patients with multiple sclerosis were enrolled 
to receive three different doses of BG-12 or  placebo.13 
Compared with placebo, BG-12 at 240 mg three times a day 
(TID) reduced the number of GdE lesions from week 12 to 
24 by 69% (P , 0.0001). The numbers of new or enlarging 
T
2
-hyperintense and new T
1
-hypointense lesions were also 
reduced (P = 0.0006 and P = 0.014, respectively).
A phase III program with multicenter, 2-year, random-
ized, double-blind, placebo-controlled, dose-comparison 
studies was undertaken in Europe and in North America 
to determine the long-term safety and efficacy of BG-12. 
This included the DEFINE (Efficacy and Safety of Oral 
BG00012 in Relapsing–Remitting Multiple Sclerosis) and 
CONFIRM (Efficacy and Safety Study of Oral BG00012 
with Active Reference in Relapsing–Remitting Multiple 
Sclerosis) studies; the CONFIRM study also contains a GA 
group to compare BG-12 with an established therapy. Both 
trials have been completed and results recently presented. 
The DEFINE study showed how BG-12 reduced the risk 
of relapse by 49% in the twice a day (BID) group (hazard 
ratio 0.51, 95% confidence interval 0.40–0.66; P , 0.0001) 
and by 50% in the TID, group (hazard ratio 0.50, 95% con-
fidence interval 0.39–0.65; P , 0.0001). Moreover, BG-12 
BID reduced the annualized relapse rate (ARR) by 53%, 
while BG-12 TID reduced the ARR by 48% (P , 0.0001 for 
both).14 MRI scans were performed at baseline, 24 weeks, 1 
year, and 2 years to determine the number of T
2
-hyperintense 
lesions, Gd+ lesions, and T
1
-hypointense lesions (a tertiary 
end point). At 2 years, results demonstrated that RRMS 
patients receiving BG-12 experienced significant reduc-
tions in the number of brain lesions compared to patients 
on placebo.15 CONFIRM was a multicenter,  randomized, 
placebo-controlled, reference comparator study that evalu-
ated the efficacy and safety of BG-12 over 2 years in RRMS 
patients. BG-12 BID and TID significantly reduced the ARR 
by 44% (P , 0.0001) and 51% (P , 0.0001), respectively, 
versus placebo at 2 years. GA reduced the ARR by 29% 
(P = 0.0128). BG-12 BID and TID and GA reduced the risk 
of relapse by 34% (P = 0.0020), 45% (P , 0.0001), and 29% 
(P = 0.0097), respectively. Reduction in 12-week confirmed 
disability progression was 21% for BG-12 BID, 24% for 
TID, and 7% for GA (nonsignificant for all) versus placebo 
at 2 years. The incidence of adverse events (AEs) and serious 
AEs (SAEs) was similar across all groups.16
Teriflunomide is the active metabolite of leflunomide. 
Leflunomide blocks de novo pyrimidine synthesis by 
 inhibiting dihydroorotate dehydrogenase in T cells and other 
rapidly dividing cell populations, leading to a decrease in 
DNA  synthesis.17 Leflunomide is licensed for the treatment 
of rheumatoid arthritis and is also effective in experimental 
autoimmune neuritis and rat experimental autoimmune 
encephalomyelitis (EAE).18,19 A 36-week, randomized, 
 double-blind, placebo-controlled, parallel-group trial 
assessed the safety and efficacy of this new drug on MS: 
179 patients (157 with RRMS, 29 with SPMS) were treated 
with placebo (n = 61), teriflunomide 7 mg/day (n = 61), and 
teriflunomide 14 mg/day (n = 57) for 36 weeks. Treatment 
with teriflunomide 7 or 14 mg/day resulted in significant 
suppression of .61% of MRI activity relative to placebo 
(P , 0.03 at 7 mg/day and P , 0.001 at 14 mg/day). The 
annualized relapse rate between placebo and teriflunomide 
14 mg/day was similar to that reported for IFNβ and GA 
(32%). The higher dose of teriflunomide (14 mg/day) appears 
to be more effective than the 7 mg/day dose in terms of 
relapse rate, although no dose effect was observed on primary 
end points such as Gd+ lesions and new/enlarging T
2
 lesions.20 
These results have been recently confirmed in an open-label, 
long-term extension of this study. Disability progression, 
ARRs, and MRI activity remained low  throughout the course 
of the extension, providing evidence that the previously 
reported beneficial effects of teriflunomide on clinical and 
MRI end points are maintained over the long term, for up 
to 8.5 years.21
A large, randomized, double-blind, placebo-controlled 
phase III parallel-group study has been completed (TEMSO). 
Patient with RRMS or progressive relapsing MS (n = 1088) 
were randomized (1:1:1) to receive placebo, teriflunomide 
7 mg/day or 14 mg/day for 108 weeks. Teriflunomide reduced 
the ARR (0.54 for placebo vs 0.37 for teriflunomide at either 
7 or 14 mg), with relative-risk reductions of 31.2% and 
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31.5%, respectively (P , 0.001 for both comparisons with 
placebo). The proportion of patients with confirmed disability 
progression was 27.3% with placebo, 21.7% with terifluno-
mide at 7 mg (P = 0.08), and 20.2% with teriflunomide at 
14 mg (P = 0.03). Both teriflunomide doses were superior 
to placebo on a range of end points measured by MRI. 
 Diarrhea, nausea, and hair thinning were more  common with 
teriflunomide than with placebo. The incidence of elevated 
alanine aminotransferase levels ($1 times the upper limit of 
the normal range) was higher with teriflunomide at 7 mg and 
14 mg (54.0% and 57.3%, respectively) than with placebo 
(35.9%); the incidence of levels that were at least three times 
the upper limit of the normal range was similar in the lower- 
and higher-dose teriflunomide groups and the placebo group 
(6.3%, 6.7%, and 6.7%, respectively). Serious infections 
were reported in 1.6%, 2.5%, and 2.2% of patients in the three 
groups, respectively.22 Trials investigating teriflunomide in 
clinically isolated syndrome are under way as combination 
studies of teriflunomide with IFNβ or GA. The last mentioned 
study seems to be really meaningful, exploring the possibility 
of using teriflunomide as an add-on therapy.
Laquinimod is a novel synthetic compound with oral bio-
availability that is in development as an oral formulation for 
the treatment of MS. Laquinimod was effective in a rat model 
of EAE, in which its efficacy was ascribed to modulation of 
the balance of Th cells’ 1 and 2 induction of transforming 
growth factor β.23 However, the exact mechanism of action 
in MS patients is still ambiguous. The efficacy of laquini-
mod was studied in two phase II studies. The first phase II 
clinical trials showed inconclusive results on the effect of a 
0.3 mg dose and led to further exploration of the therapeu-
tic dose in an additional phase IIb study. The second study 
was a phase IIb, multinational, randomized, double-blind, 
parallel-group, placebo-controlled 36-week study evaluating 
the efficacy, tolerability, and safety of two daily oral doses 
(0.3 and 0.6 mg) of laquinimod (as compared to placebo) in 
subjects with RRMS. The statistical analysis on the intention-
to-treat population for the primary end point demonstrated 
a statistically significant treatment effect of laquinimod 
0.6 mg compared to placebo (P = 0.0048), with a reduction 
of 40% in the cumulative number of Gd+ lesions at weeks 
24, 28, 32, and 36. A nonsignificant treatment effect of 8% 
was observed with laquinimod 0.3 mg (P = 0.6740).24 Given 
these results, the sponsor moved forward with phase III clini-
cal trials of laquinimod at the 0.6 mg/day dose, which have 
just been completed. Overall, the results from the phase III 
studies indicate that while laquinimod is relatively effective 
in reducing disease activity as measured by relapse rate, it is 
very effective on some MRI markers of neurodegeneration, 
indicating a possible role as neuroprotective treatment in MS. 
Treatment with laquinimod as compared with placebo was 
associated with a modest reduction in the mean (±standard 
error) ARR (0.30 ± 0.02 vs 0.39 ± 0.03, P = 0.002) and with 
a reduction in the risk of confirmed disability progression 
(11.1% vs 15.7%, hazard ratio 0.64, 95% confidence inter-
val 0.45–0.91; P = 0.01). The mean cumulative numbers of 
Gd+ lesions and new or enlarging lesions on T
2
-weighted 
images were lower for patients receiving laquinimod than 
for those receiving placebo (1.33 ± 0.14 vs 2.12 ± 0.22 and 
5.03 ± 0.08 vs 7.14 ± 0.07, respectively; P , 0.001 for both 
comparisons).25 The most significant side effects appeared 
to be urinary tract infections and a temporary  abnormality 
in liver-function tests. Based on a thorough review of all 
laquinimod clinical data available to date, the primary 
safety concerns include potential hepatotoxicity and a pos-
sible proinflammatory effect. Four SAEs were reported: 
pleuritis, Budd–Chiari syndrome, pituitary adenoma with 
hemorrhage, and a possible diagnosis of Crohn’s disease. 
 Pharyngolaryngeal pain, dyspepsia, and ankle edema were 
also observed. Recently, pooled analyses assessing the effect 
of laquinimod on relapse, disability, and brain-atrophy mea-
sures from the completed phase III trials ALLEGRO and 
BRAVO have been presented. Pooled analyses on ARR found 
that laquinimod reduced relapse rate by 21.4% (0.30 ARR 
for laquinimod vs 0.38 for placebo patients, P = 0.0005). 
Pooled analyses on the risk to confirmed disability progres-
sion sustained for 3 months found laquinimod significantly 
reduced the risk (34.2%, P = 0.0017) compared to placebo. 
Using a more stringent criterion of sustained disability for 
6 months, there was a significant reduction by laquinimod 
(46%, P , 0.0001). Percent change in brain volume was 
reduced by 30% (-0.835 vs -1.188% for laquinimod and 
placebo patients, P , 0.001).26
Introduction to the compound
Fingolimod (FTY720) is an oral drug with a novel mecha-
nism of action and unique immunological and neurobio-
logical properties. Fingolimod is a structural analogue of 
sphingosine that does not impair T- and B-cell activation, 
proliferation, and effective function, but interferes with cell 
traffic between lymphoid organs and blood.27 Moreover, 
fingolimod is a lipophilic compound that can cross the blood–
brain barrier, and research suggests that its neuroprotective 
properties might be a reflection of its ability to directly inter-
act with specific receptors on neurons and glia.28 Following 
preclinical studies in animal models of organ transplantation, 
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Figure 1 Fingolimod chemical structure.
fingolimod was first evaluated for the prevention of allograft 
rejection in renal transplant patients, but phase III trials failed 
to show benefit over standard treatments.29 Encouraging 
results obtained from animal models of EAE provided the 
rationale for clinical evaluation in humans, and one phase 
II proof-of-concept study confirmed the favorable effect of 
fingolimod oral therapy on standardized measures of disease 
activity in patients with RRMS.
Chemistry, pharmacodynamics,  
and pharmacokinetics
Fingolimod (2-amino-2-[2-{4-octylphenyl}ethyl]-1,3-
propanediol) is an immunosuppressive synthetic compound 
derived from myriocin, a metabolite isolated from the  fungus 
Isaria sinclairii, used as a drug in Oriental medicine30 
 (Figure 1). This compound is the sphingosine-1-phosphate 
(S1P) receptor modulator. S1P is produced by phospho-
rylation of sphingosine by ubiquitously expressed sphin-
gosine kinases, a breakdown product of the cell-membrane 
constituent sphingomyelin. It is present at concentrations 
of 100–1000 nmol/L in blood, and as with most small 
lipids is preferentially bound to albumin and other plasma 
 proteins.31 S1P could act both as second messenger and as 
an extracellular ligand for a family of plasma-membrane 
G protein-coupled receptors.32 There are five known S1P 
receptor subtypes – S1P
1–5
 – and these are expressed on a 
wide range of cell types, including lymphocytes and neural 
cells (Table 2). Each S1P receptor subtype is associated with 
at least one subclass of G protein, which activate different 
intracellular signaling pathways.33 The receptors S1P
1–3
 are 
widely expressed by a variety of tissues, whereas S1P
4
 is 
exclusively found on lymphoid and hematopoietic tissues 
and S1P
5
 is mainly expressed in the CNS.34 The ubiquitous 
expression of S1P receptors and their coupling to different 
G proteins explains the varied biological effects of the S1P/
S1P-receptor system.35 In particular, S1P1 expressed on 
lymphocytes regulates the normal egress of lymphocytes 
from lymphoid tissues,36 whereas S1P receptors expressed 
in the CNS have been shown to modulate several functions, 
such as neurogenesis, neural function, and migration.34 Thus, 
this explains the possible clinical and adverse effects that 
agents like fingolimod targeting the S1P receptor system 
can  potentially induce. As a structural analogue of natural 
sphingosine, fingolimod after ingestion can undergo rapid 
phosphorylation in vivo, especially in the liver, by sphin-
gosine kinase-2 to produce the phosphorylated form of the 
compound. The latter can bind four of the five receptor sub-
types with high affinity: S1P
1
–S1P
3
–S1P
4
–S1P
5
.37 Following 
engagement through the agonist, the S1P
1
 receptor is internal-
ized and can no longer bind to its natural circulating ligand, 
S1P, inducing a long-lasting internalization, ubiquitination, 
and intracellular degradation of the receptors, rendering the 
cells unresponsive to endogenous S1P.38 The effects of fin-
golimod reflect the ubiquitous expression of the S1P receptor 
and are shown on different levels, principally regarding the 
immune system and the CNS. Following administration, 
blood concentration increases slowly to reach peak values at 
8–36 hours postdosing. The elimination half-life of fingoli-
mod averages 8.8 days, so a once-daily dosing is permitted. 
Clearance of fingolimod depends mainly on hepatic oxidative 
metabolism, and none of the identified metabolites possess 
immunomodulatory activity.39 The main pharmacodynamic 
effect of fingolimod consistently observed in human studies 
has been temporary reversible lymphopenia.39,40
Clinical efficacy
On the basis of the results demonstrating the potency of 
fingolimod in human organ transplantation,40 preclinical 
studies in various EAE models were designed.41 These stud-
ies demonstrated the capability of fingolimod in preventing 
and treating EAE. Delivery of fingolimod from the day of 
immunization or at a presymptomatic disease stage prevents 
the development of neurological signs in both monophasic 
and relapsing forms of EAE.41,42 Fingolimod is currently 
being assessed in one of the largest phase III MS study pro-
grams ever undertaken, having shown promise in a phase II, 
6-month, placebo-controlled study in patients with relapsing 
MS in which oral fingolimod compared with placebo signifi-
cantly reduced the ARR and inflammatory activity according 
to MRI scans (Table 3).
Phase II studies
The first study evaluating the activity of fingolimod in patients 
with RRMS was a randomized, double-blind, placebo-
 controlled, 6-month study.43 The study was designed to 
explore safety and tolerability and the treatment effect on MRI 
lesion parameters but not on clinical outcomes. In the core 
study, patients were randomly assigned, in a 1:1:1 ratio, to 
1.25 mg of fingolimod, 5.0 mg of fingolimod, or a matching 
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Table 2 Distribution and functions of S1P receptors
Receptors Cellular distribution Fingolimod  
binding
Key functions
S1P1 (EDG1) • Lymphocytes, mast cells, eosinophils 
•  Neurons, astrocytes, oligodendrocytes, microglia 
•   Atrial myocytes, endothelium smooth-muscle cells,  
Schwann cells
Yes •  Lymphocyte egress from secondary lymphoid organs 
•  Neural cell migration/function 
•   Embryonic development of cardiovascular  
and nervous systems
•  Blood-vessel formation 
•  Endothelial barrier function
S1P2 (EDG5) •  Neurons, microglia, astrocytes 
•  Smooth-muscle cells, Schwann cells
No •  Vascular tone 
•  Endothelial barrier function 
•  Inner-ear maintenance affecting hearing and balance 
•  Nerve conduction
S1P3 (EDG3) •  Neurons, astrocytes, microglia 
•  Atrial myocytes, endothelium, smooth-muscle cells 
•  Lung 
•  Kidney 
•  Intestine 
•  Cartilage 
•  Schwann cells
Yes •  Endothelial barrier function 
•  Neural cell migration/function
S1P4 (EDG6) •  Leukocytes 
•  Schwann cells
Yes Unknown
S1P5 (EDG8) •  Oligodendrocytes, microglia, astrocytes Yes •  Oligodendrocyte function 
•  NK-cell migration
Abbreviations: EDG, endothelial differentiation sphingolipid G protein-coupled receptor; NK, natural killer; S1P, sphingosine 1-phospate.
Table 3 Summary of fingolimod trials
Study Study design Treatment in study Primary  
end points
Eligibility  
criteria
Main results
Kappos et al43 Phase II, 6-month, double- 
blind, parallel-group, placebo- 
controlled, multicenter
Fingolimod 
5 mg orally, daily 
Fingolimod 
1.25 mg orally,  
daily/placebo
Total no  
of Gd+ lesions  
on T1-w MRI  
at month 6
RRMS, SPMS 
18–60 years 
EDSS 0–6, no  
evidence of relapse  
in the last 30 days
Patients free from Gd+ 
lesions: 82%*
Cohen et al46  
(TRANSFORMS)
Phase III, 12-month, double- 
blind, double-dummy,  
parallel-group, active- 
controlled, multicenter
Fingolimod 
1.25 mg orally, daily 
Fingolimod 
0.5 mg orally, daily 
IFNβ-1a 30 μg 
intramuscularly, weekly
ARR over 
12 months
RRMS 
18–55 years 
EDSS 0–5.5, recent  
history of relapse
ARR: 0.20*; 0.16* 
Patients 
free from 
relapses: 79.8%*; 82.6%*
Kappos et al47  
(FREEDOMS)
Phase III, 24-month, double- 
blind, parallel-group, placebo- 
controlled, multicenter
Fingolimod 
1.25 mg orally, daily 
Fingolimod 
0.5 mg orally,  
daily/placebo
ARR over 
24 months
RRMS 
18–55 years 
EDSS 0–5.5, recent  
history of clinical  
relapse
ARR: 0.16*; 0.18* 
Patients free from relapses: 
74.7% ± 2.2%* 
70.4% ± 2.3%*
Note: *P , 0.001.
Abbreviations: ARR, annualized relapse rate for confirmed relapses; EDSS, expanded disability status scale; Gd+, gadolinium-enhanced; IFNβ-1a, interferon beta-1a; MRI, 
magnetic resonance imaging; RRMS, relapsing–remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; T1-w: T1-weighted.
placebo given once daily as oral capsules. The intention-to-
treat population comprised 277 patients, of which 255 (92%) 
completed the study. The primary efficacy end point of the 
study was the total number of Gd+ lesions per patient recorded 
on T
1
-weighted MRI at monthly intervals for 6 months. 
Secondary MRI variables included the total volume of Gd+ 
lesions per patient, the proportion of patients with Gd+ lesions, 
the total number of new lesions per patient on T
2
-weighted 
images, changes in lesion volume on T
2
-weighted images, and 
brain volume from baseline to month 6. Clinical end points 
included the number of patients remaining free of relapse, the 
ARR, and the time to the first relapse.
The total cumulative numbers of lesions per patient on 
postbaseline, monthly Gd+ T
1
-weighted MRI scans were 
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lower in both fingolimod groups than in the placebo group 
(P , 0.001 for the 1.25 mg dose and P = 0.006 for the 5.0 mg 
dose). At month 6, the proportion of patients who were free of 
Gd+ lesions was greater in both fingolimod groups than in the 
placebo group (P , 0.001 for both comparisons). Regarding 
the clinical end point, significant improvements over placebo 
were observed in the fingolimod groups, including a relative 
reduction in the ARR (by 53% in the 5.0 mg group and by 
55% in the 1.25 mg group).
After the core-study completion, patients could enter a 
dose, open-label, uncontrolled, active-drug study  extension. 
Placebo recipients were rerandomized to one of the FTY720 
doses; those already receiving FTY720 continued at the 
same dose.44,45 During the month 15–24 study visits, patients 
receiving FTY720 5.0 mg were switched to 1.25 mg because 
a benefit–risk assessment indicated that the higher dose 
offered no efficacy advantage and possibly a less favorable 
safety profile.
Of the 250 patients who entered the extension, 189 (75.6%) 
completed to month 24 and 173 (69%) to month 36. In the 
group of patients who switched from placebo to  fingolimod, the 
number of Gd+ lesions decreased markedly following initiation 
of fingolimod treatment to 0.4 at month 12 and remained low 
(0.1) at month 36, and relapse rate to a level comparable with 
that of patients treated with fingolimod in the core study. The 
proportion of patients free from Gd+ lesions in the placebo/
fingolimod group was 50% at baseline, 47% at month 6, and 
89% at month 36. The proportions of patients free from Gd+ 
lesions in the fingolimod 1.25 mg and 5.0/1.25 mg groups at 
baseline were 52% and 48%, respectively; at month 36, the 
corresponding proportions were 88% and 89%, respectively. 
In the continuous-fingolimod groups, the mean number of 
Gd+ lesions was 3.2 at baseline, 1.4 at month 6, and 0.2 at 
month 36 in the 1.25 mg group, and 2.6 at baseline, 0.4 at 
month 6, and 0.3 at month 36 in the 5.0/1.25 mg group. The 
mean number of new T
2
 lesions acquired across all treatment 
groups was 0.6 at month 24 (since month 12) and 0.7 at month 
36 (since month 24). Considering clinical outcomes at month 
36, the ARR was 0.20 and 0.21 in the fingolimod 1.25 mg 
and 5.0/1.25 mg groups, respectively, and 0.31 in the placebo/
fingolimod group. The proportions of patients relapse-free at 
month 36 were 68% in the fingolimod 1.25 mg group and 73% 
in the fingolimod 5.0/1.25 mg group rather than estimated 51% 
of patients in the placebo/fingolimod group at month 36.
Phase III studies
On the basis of the results detected from phase II studies, 
two multicenter, randomized, double-blind phase III tri-
als have been designed.46,47 As these results suggest that 
the therapeutic benefits attributed to fingolimod might 
exceed those expected from approved disease-modifying 
injectable therapies such as IFNβ or glatiramer acetate, 
the Trial Assessing Injectable Interferon versus FTY720 
Oral in Relapsing–Remitting Multiple Sclerosis (TRANS-
FORMS)46 tested directly this hypothesis. In this 12-month, 
double-blind, double-dummy study, they randomly assigned 
1292 patients between 18 and 55 years of age with RRMS, 
according to the McDonald criteria,48 who had had a recent 
history of at least one relapse in the last year before screen-
ing to receive either oral fingolimod at a daily dose of either 
1.25 or 0.5 mg or intramuscular IFNβ-1a at a weekly dose 
of 30 μg. The primary efficacy end point was the ARR. Key 
secondary end points were the number of new or enlarged 
lesions on T
2
-weighted MRI scans at 12 months and the 
time to confirmed disability progression meant a progres-
sion of disability that was sustained for at least 3 months. 
In all, 1153 patients (89%) completed the study, and 1123 
(87%) continued to receive the assigned study drug. There 
was a significantly greater reduction in the ARRs in both 
fingolimod groups than in the IFN group. The ARR was 
lower with fingolimod (0.5 mg, 0.16; 1.25 mg, 0.20) than 
with IFNβ-1a (0.33, P , 0.001). More patients treated 
with fingolimod remained free from relapses (80%–83%) 
compared with IFNβ-1a (69%, P , 0.001). The propor-
tion of patients with confirmed disability progression was 
low and similar in all groups (6%–8%). Over the treat-
ment period of 12 months, patients in both fingolimod 
groups had fewer new or enlarged hyperintense lesions on 
T
2
-weighted images than those receiving IFNβ-1a (mean 
number, 0.5 mg, 1.7; 1.25 mg, 1.5; IFNβ-1a, 2.6; P , 0.001 
and P = 0.004). Patients free from Gd+ lesions were also 
lower with fingolimod (0.5 mg, 90.1%; 1.25 mg, 91.2%) 
compared with those taking IFNβ-1a (80.8%, P , 0.001 
for both groups).47
The second phase III study investigating fingolimod is the 
FTY720 Research Evaluating Effects of Daily Oral Therapy 
in Multiple Sclerosis (FREEDOMS) trial,47 a 24-month, 
double-blind, placebo-controlled randomized study. A total 
of 1272 patients between 18 and 55 years of age with RRMS 
defined by the McDonald criteria who had a score of 0–5.5 on 
the expanded disability status scale and had had one or more 
relapses in the previous year or two or more in the previous 
2 years were enrolled. Patients received oral fingolimod at 
a dose of 0.5 mg or 1.25 mg daily or placebo. As with the 
TRANSFORMS study, the primary end point was the ARR, 
and the secondary end point was represented by the time 
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to disability progression. MRI measures of inflammation, 
burden of disease, and tissue destruction in patients were 
also analyzed. A total of 1033 patients (81.2%) completed 
the 24-month study. All clinical and MRI-related efficacy 
end points significantly favored both doses of fingolimod 
over placebo, and there were no significant differences in 
efficacy between the two fingolimod doses: the aggregate 
ARR was lower with fingolimod at a dose of 0.5 mg (0.18) 
and fingolimod at a dose of 1.25 mg (0.16) than with placebo 
(0.40), representing relative reductions of 54% and 60%, 
respectively, in the aggregate ARR (P , 0.001 for both 
groups). In the fingolimod groups compared with the placebo 
group, the time to a first relapse was longer, the risk of relapse 
was reduced, and proportionately more patients remained free 
of relapse during the 24-month period. Fingolimod reduced 
the risk of disability progression, confirmed after 3 months, 
over the 24-month study period (hazard ratios 0.68 for the 
1.25 mg dose and 0.70 for the 0.5 mg dose, P , 0.02).47 
The cumulative probability of disability progression (con-
firmed after 3 months) was 17.7% for 0.5 mg of fingolimod, 
16.6% for 1.25 mg of fingolimod, and 24.1% for placebo. 
At month 24, patients receiving fingolimod had fewer new 
or enlarged hyperintense lesions on T
2
-weighted images than 
those in the placebo group (means for 0.5 and 1.25 mg, 2.5; 
placebo, 9.8; P , 0.001). Fingolimod was also superior to 
placebo with regard to other MRI measures of disease activity 
as Gd+ lesions.47 Moreover, and really interestingly, in patients 
treated with fingolimod, the brain reduction was smaller than 
in patients treated with placebo.
Safety and tolerability
The safety profile of fingolimod has been extensively studied, 
based on acquired experience, and the available data indicate 
that the drug has a relatively good safety profile. It is clearly 
known that the incidence of AEs is dose-dependent and 
increases with rising doses of fingolimod.43,46,47 The phase II 
study showed a higher incidence of AEs in the group of 
patients treated with a high dose of fingolimod (5.0 mg; 96% 
against 82% in the placebo group and 84% in the fingolimod 
1.25 mg group). In phase III trials, the incidence of AEs was 
approximately the same across the study groups. AEs related 
to fingolimod included infections, particularly respiratory, 
urinary tract, and herpes virus infections, increased levels 
of alanine aminotransferase, bradycardia, and atrioventricu-
lar block at the time of treatment initiation, hypertension, 
and macular edema. The incidence of SAEs was compa-
rable among the study groups, with the exception of the 
 TRANSFORMS trial, in which SAEs were more frequent in 
patients assigned to a higher dose (1.25 mg) of fingolimod 
(11%) than in those receiving 0.5 mg (7%).
Even though the pathophysiology of macular edema 
in patients treated with fingolimod is still unclear, it was 
confirmed in 13 patients receiving fingolimod in phase III 
trials, of which eleven were treated with 1.25 mg. Most 
cases occurred within the first 3–4 months and resolved after 
treatment discontinuation.46,47 No cases were detected during 
phase II studies in MS.43
As expected, the drug induced a decrease of peripheral 
blood lymphocyte counts to 20%–30% of baseline values. 
Lymphocyte counts remained stable throughout the treatment 
period, and returned to baseline values within weeks after 
treatment discontinuation. As a consequence of the effects of 
fingolimod on circulating lymphocyte, the drug apparently 
increases the risk of infections. In phase III trials, the overall 
incidence of infections was similar across the study groups, in 
the range between 51% and 72%. Mild and moderate upper 
and lower respiratory tract infections occurred more frequently 
among patients receiving fingolimod. Herpes zoster occurred 
in six patients during months 0–36 in phase II studies.43 Herpes 
virus infections were diagnosed in 2%–9% of patients. In the 
FREEDOMS study, herpes virus infections were reported in 
similar proportions across study groups (1.25 mg, 5.8%; 0.5 mg, 
8.7%; placebo, 7.9%). On the contrary, in the  TRANSFORMS 
study, these were more common in the 1.25 mg group (5.5% 
of patients) than in the 0.5 mg and IFNβ-1a groups (2.1% and 
2.8%, respectively). Most herpes virus infections were mild, 
but a total of six SAEs were reported, including one case of 
fatal disseminated varicella zoster virus infection and one 
case of fatal herpes simplex virus type 1 encephalitis, both in 
patients assigned to fingolimod 1.25 mg. Both patients were 
undergoing concomitant corticosteroid treatment when the 
infection occurred.46,47 Thus, a possible increase in the risk 
of reactivation of latent herpes should be deeply investigated 
when considering fingolimod treatment. Besides lymphopenia, 
asymptomatic elevation of liver enzyme levels was the most fre-
quent laboratory abnormality and occurred in a dose- dependent 
manner within the whole range of doses investigated. In clinical 
studies, alanine aminotransferase levels returned to normal 
values after treatment discontinuation. In none of these cases 
were other signs or symptoms of significant hepatocellular 
injury observed.46,47 Moreover, fingolimod induced a small, 
dose-dependent increase in airway resistance upon treatment 
initiation, with no evidence for further progression with con-
tinuous dosing.43,46,47
As was expected based on previous findings, though 
rarely symptomatic, a dose-dependent reduction in heart rate 
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occurred within 6 hours after administration of the first dose. 
This drop in heart rate was already evident within 1 hour 
postdosing, reached a maximum mean reduction of approxi-
mately 10 beats/minute at 4–5 hours, began to attenuate at 
6 hours, and returned towards the baseline values.46,47
In phase III trials, symptomatic bradycardia after the 
first dose of fingolimod, mainly dizziness, chest discomfort, 
or palpitations, was observed in ,1% of patients. No cases 
of syncope have been observed. Most events were mild to 
moderate in severity and resolved within 24 hours without 
requiring pharmacological interventions. There were no 
episodes of symptomatic bradycardia occurring beyond 
24 hours, and no clinically significant effect on heart rate 
was observed with sustained administration of the drug.46,47 
Although during clinical trials, pharmacological treatment 
has never been required to treat bradycardia, it has been sug-
gested that intravenous atropine can ameliorate the negative 
effect of fingolimod on cardiac rhythm.49 In addition to tran-
sient changes in cardiac rhythm, fingolimod induced cardiac 
conduction abnormalities, including first- and second-degree 
atrioventricular block. In the phase II trial, transient Mobitz 
type 1 second-degree atrioventricular block occurred on the 
first day postdosing in eight of 65 patients who received 
fingolimod.43 In phase III trials, first- and second-degree atrio-
ventricular blocks were infrequently reported (0.4%–1.4% of 
patients), and these were not symptomatic. However, in the 
FREEDOMS study, electrocardiography performed on day 1 
postdosing revealed first- and second-degree atrioventricular 
block in seven and 0.6% of patients respectively. No effect 
on atrioventricular conduction was observed with continued 
treatment beyond 24 hours.46,47 Initial administration of fin-
golimod was also associated with a mild reduction in mean 
arterial blood pressure within 4–5 hours postdosing. This 
transient reduction in mean arterial pressure was followed by 
a small and sustained increase (2–3 mmHg over the baseline 
values) during the first 6 months of treatment, with no further 
changes in the subsequent months. In phase III trials, hyper-
tension was reported in 4%–6% of participants.46,47
Malignant neoplasms were reported in patients under-
going therapy with fingolimod in phase III trials, including 
localized skin cancer (Bowen’s disease, one case; basal cell 
carcinoma, ten cases; malignant melanoma, four cases), 
all of which were successfully excised, and breast cancer 
(five cases). One woman died from metastatic breast cancer 
10 months after discontinuing fingolimod.46 Both skin and 
breast cancer were also reported in the control groups (six 
and three cases in total, respectively). The number of events 
was not enough to establish a statistical association between 
fingolimod and the risk of cancer in clinical trials. However, 
further long-term observation is needed before definitive 
conclusions can be reached.
Besides more frequent SAEs being observed, two cases 
of particular interest were experienced during the clinical 
trials. In the phase II trial, one case of posterior reversible 
encephalopathy syndrome occurred in a woman with no 
evident predisposing factors after 10 weeks of treatment with 
5 mg of fingolimod. The symptoms and MRI abnormalities 
improved 72 hours after discontinuation of medication, leav-
ing residual neurological deficits.43
A case of temporo-occipital hemorrhagic and centrally 
necrotic focal encephalitis of unknown etiology was reported 
in a woman after 7 months of treatment with 1.25 mg 
of fingolimod. Although bacterial and viral causes were 
excluded, antimicrobial treatment was administered. The 
patient recovered with sequelae.50
Future perspectives
The positive results gained from the studies described above 
was followed by authorization in Russia and the US. Then fin-
golimod (Gilenya, Novartis, Basel, Switzerland) was approved 
in Europe in June 2011 to treat adults with highly active MS. 
As the FDA listed several recommendations for clinicians 
using Gilenya, the EMA made all European countries aware 
of different conditions or restrictions with regard to the safe 
and effective use of the compound.51 Nonetheless, at present 
several phase III trial extension studies are ongoing to collect 
long-term data on the safety and effectiveness of fingolimod, 
especially exploring the incidence of selected safety-related 
outcomes of fingolimod treatment during follow-up. Results 
from an extension study have been recently presented. Newer 
agents that are more selective for the different types of S1P 
receptors are currently in development to minimize the AEs 
observed with fingolimod.52 In order to focus on cardiac safety 
after the first dose of fingolimod 0.5 mg, the FIRST study 
has included relapsing MS patients both without cardiac risk 
factors and with cardiac conditions not included in previous 
fingolimod clinical trials: overall incidence of atrioventricular 
blocks on Holter electrocardiography was low, irrespective 
of on- or off-site first-dose administration or the presence of 
potential cardiac risk factors. These results are similar to those 
observed in fingolimod trials and confirm the benign nature of 
the cardiac effects of treatment initiation with fingolimod.53 In 
addition, a fundamental purpose is continuously to monitor, 
evaluate, and assess for major and minor teratogenic effects 
in the offspring of women exposed to fingolimod before 
(up to 8 weeks before last menstrual period) and during 
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pregnancy in routine clinical practice. The overall aim is to 
collect and evaluate data on maternal, fetal, and infant out-
comes and compare it with reference populations through 
the Multi-National Gilenya Pregnancy Exposure Registry in 
Multiple Sclerosis (MS).54
Conclusion
In the last few years, impressive research and development 
programs for drug treatments in MS have been developed. 
The five oral therapies discussed (cladribine, fingolimod, 
laquinimod, BG-12, and teriflunomide) have just com-
pleted phase III studies, and some have just been licensed. 
Maintaining adherence to DMDs is a daily challenge to 
those who manage and coordinate care for MS patients. It 
is well known that patients who have more positive feelings 
towards prescribed therapy adhere more closely to their 
therapeutic regimen. The development of drugs with easier 
administration, such as oral agents discussed above, would 
further promote adherence and could increase the number 
of patients with MS in treatment, reducing discomfort and 
inconvenience, making it easier for patients to adhere to 
their treatment regimen and thus improving efficacy. The 
most challenging aspect for physicians will be making their 
patients understand the need of balancing for each case, 
the pros and cons of new oral treatment, where serious side 
effects may outweigh benefits in certain individuals. This is 
particularly important given the lack of long-term safety data 
with these new oral treatments versus currently approved 
disease-modifying therapies. Neurologists are starting to 
use more powerful but potentially dangerous drugs in the 
treatment of MS. Moreover, the potential combination of oral 
drugs and IFNβ or GA needs to be tested. More information 
regarding the mechanism of action and safety of oral drugs 
would assist in the design of such combination studies. Safety 
is likely to become the most important factor in the future 
development of MS drugs. New oral drugs for MS need to 
be placed within this evolving marketplace, where ease of 
delivery together with efficacy and side effects need to be 
balanced against the known issues but also the known long-
term safety of standard injectables.
Fingolimod is the first of a new class of immunosup-
pressants with a unique mode of action. The preventive and 
therapeutic effects of oral fingolimod in various models 
of EAE and its ability to penetrate the blood–brain barrier 
make it an attractive candidate for use in the treatment of 
MS. However, safety concerns include the known pharma-
codynamic effect of the drug on heart rate and rhythm. In 
the last few months, the safety profile of the compound has 
been extremely focused since the EMA decided to review 
Gilenya following cases of death and serious cardiovascular 
events in patients who had recently started treatment with the 
medicine. While the review was ongoing, the CHMP advised 
health-care professionals to intensify monitoring of patients 
after the first dose.55 During the last few months, the review-
ing process has been concluded, and CHMP stated that the 
benefits of Gilenya continue to outweigh its risks but recom-
mended changes to the product information to strengthen the 
warnings and ensure close monitoring of all patients follow-
ing the first dose.56 Moreover, previous reports of macular 
edema in the fingolimod transplant program, and experience 
of seven cases of melanoma, squamous cell, and basal cell 
carcinomas should require careful safety monitoring.
In conclusion, while the availability of oral therapies has 
been much anticipated by physicians and patients, in clinical 
practice neurologists will need to be cautious in selecting 
such therapies, which may appear to have efficacy and con-
venience advantages versus current therapies, but may also 
carry novel safety and tolerability concerns. The decision 
to use these new therapies will most likely be based on an 
overall assessment of efficacy, safety, tolerability, adher-
ence, potential need for monitoring, and cost effectiveness. 
Although better patient compliance is expected with the oral 
agents compared with the injectables, the safety profiles of 
these new oral drugs will have to be watched carefully. The 
safety of drug combinations will be crucial to future therapeu-
tic decision-making, and more research is needed to compare 
escalation and induction treatment strategies.
Disclosure
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